Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 3
2017 1
2019 3
2020 1
2021 2
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Emerging drugs for the treatment of obesity.
Martinussen C, Bojsen-Moller KN, Svane MS, Dejgaard TF, Madsbad S. Martinussen C, et al. Among authors: bojsen moller kn. Expert Opin Emerg Drugs. 2017 Mar;22(1):87-99. doi: 10.1080/14728214.2017.1269744. Epub 2016 Dec 16. Expert Opin Emerg Drugs. 2017. PMID: 27927032 Review.
Updates in weight loss surgery and gastrointestinal peptides.
Svane MS, Bojsen-Møller KN, Madsbad S, Holst JJ. Svane MS, et al. Among authors: bojsen moller kn. Curr Opin Endocrinol Diabetes Obes. 2015 Feb;22(1):21-8. doi: 10.1097/MED.0000000000000131. Curr Opin Endocrinol Diabetes Obes. 2015. PMID: 25517025 Review.
Primary weight loss failure after Roux-en-Y gastric bypass is characterized by impaired gut-hormone mediated regulation of food intake.
Bojsen-Møller KN, Svane MS, Martinussen C, Dirksen C, Jørgensen NB, Jensen JB, Jensen CZ, Torekov SS, Kristiansen VB, Rehfeld JF, Bork-Jensen J, Grarup N, Hansen T, Hartmann B, Holst JJ, Madsbad S. Bojsen-Møller KN, et al. Int J Obes (Lond). 2023 Nov;47(11):1143-1151. doi: 10.1038/s41366-023-01372-8. Epub 2023 Aug 31. Int J Obes (Lond). 2023. PMID: 37653071 Free PMC article.
GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment.
Gabe MBN, Skov-Jeppesen K, Gasbjerg LS, Schiellerup SP, Martinussen C, Gadgaard S, Boer GA, Oeke J, Torz LJ, Veedfald S, Svane MS, Bojsen-Møller KN, Madsbad S, Holst JJ, Hartmann B, Rosenkilde MM. Gabe MBN, et al. Among authors: bojsen moller kn. Pharmacol Res. 2022 Feb;176:106058. doi: 10.1016/j.phrs.2022.106058. Epub 2022 Jan 4. Pharmacol Res. 2022. PMID: 34995796 Clinical Trial.
16 results